MAPT and Alzheimer disease: Attempts to develop antibody-based therapy targeting either Amyloid-β (Aβ) peptides or Tau, the two major aggregating proteins involved in AD pathogenesis led to conflicting clinical results and failed to show benefits on primary efficacy endpoints [9].